Jefferies has given a 'Buy' recommendation for Sai Life Sciences, projecting a target price of Rs 1,300, based on the company's resilience to Middle East impacts, cost-efficient measures, and significant project wins. Sai Life's optimistic sales growth outlook (15-20% CAGR), high EBITDA margins (28-30%), absence of destocking, and visibility in late-stage pipelines are positively influencing its future prospects.

Morgan Stanley Asia Singapore Pte has purchased approximately 800,000 shares of Sai Life Sciences for ₹79.4 crores ($10.5 million USD) at a price of ₹1015.4 per share. This investment underscores Morgan Stanley's confidence in the biotech sector and Sai Life Sciences' potential growth.

Sai Life Sciences has announced the appointment of Dr. John Pavey as a senior executive, effective April 1, 2026. With over 20 years of experience in CMC, API development, and regulatory approvals at notable companies like AstraZeneca, Dr. Pavey will be replacing Dr. Dean David Edney in his new role.